Download FREE Sample
Report Overview
Lung cancer diagnostics involves various methods and technologies to detect, confirm, and analyze lung cancer, enabling effective treatment decisions. Imaging techniques such as X-rays, CT scans, and PET scans are often the first step to identify tumours and assessing their spread. Tissue biopsies, including bronchoscopy and needle biopsies, provide definitive confirmation of cancer by analyzing cellular samples. Advances in molecular diagnostics, like Next-Generation Sequencing (NGS) and liquid biopsy, allow for detecting genetic mutations (e.g., EGFR, ALK, KRAS) critical for personalized treatment approaches. 
To learn more about the research report, download a sample report.
Rising Focus on Early Detection of Lung Cancer
Early detection of lung cancer significantly improves survival rates, as it allows for timely intervention and treatment before the disease advances. Governments and healthcare organizations are increasingly investing in screening programs, particularly for high-risk groups such as smokers and individuals with a family history of cancer. The adoption of low-dose CT (LDCT) as a screening tool has gained prominence, supported by numerous clinical studies proving its efficacy in detecting lung cancer at an earlier, more treatable stage. Public health campaigns emphasizing the benefits of early screening, combined with the availability of reimbursement for screening tests in developed economies, have further accelerated adoption. This focus on early detection not only drives the market but also aligns with the global shift toward preventative healthcare strategies aimed at reducing the burden of late-stage cancer treatments. 
To learn more about the research report, download a sample report.
Biomarker Testing in Lung Cancer Diagnostics
Biomarker testing has emerged as a groundbreaking advancement in lung cancer diagnostics, enabling personalized and precise treatment approaches. Molecular and genetic testing techniques, such as next-generation sequencing (NGS) and liquid biopsy, allow clinicians to identify specific mutations (e.g., EGFR, ALK, ROS1) and tailor therapies accordingly. Liquid biopsies, in particular, are non-invasive and provide real-time insights into tumour dynamics, enhancing their appeal for routine monitoring. Additionally, advances in artificial intelligence (AI) are transforming biomarker interpretation, improving diagnostic accuracy and speed. The integration of AI with molecular diagnostics platforms facilitates automated analysis of complex datasets, ensuring reliable and reproducible results. These advancements not only boost diagnostic efficiency but also play a critical role in advancing precision oncology, making biomarker testing a cornerstone of lung cancer diagnostics.
Competitive Landscape Analysis
The global lung cancer diagnostics market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific; Agilent Technologies; Qiagen; Abbott; Bio-Rad Laboratories, Inc.; Neogenomics Laboratories; Myriad Genetics, Inc.; and Illumina Inc. among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Scope | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| Growth | 7% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Cancer Type, Test Type and End-user |
| Regional Scope |
|
| Key Companies Mapped | F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific; Agilent Technologies; Qiagen; Abbott; Bio-Rad Laboratories, Inc.; Neogenomics Laboratories; Myriad Genetics, Inc.; and Illumina Inc. among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Market Segmentation
This report by Medi-Tech Insights provides thesize of the global lung cancer diagnostics market at theregional- and country-level from 2023 to 2030. The report further segments the market based on cancer type, test type and end-user.
- Market Size & Forecast (2023-2030), By Cancer Type, USD Million
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Market Size & Forecast (2023-2030), By Test Type, USD Million
- CA Test
- HER2 Test
- ALK Test
- Angiogenesis Inhibitors
- EGFR Mutation Test
- KRAS Mutation Test
- Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic Centers
- Others
- Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- C
- Europe
- UK
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
- North America
Frequently Asked Questions About This Report
What is the market size & forecast of the lung cancer diagnostics market?
What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the lung cancer diagnostics market?
What are the key trends defining the market?
What are the major factors impacting the market?
What are the opportunities prevailing in the market?
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
